Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
Stocks turned lower on Thursday as a wave of corporate earnings failed to impress. The Dow Jones Industrial Average slipped ...
Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular ...
Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s ...
Eli Lilly is setting the stage for a strong 2025, with its fourth-quarter results and forward guidance reflecting solid ...
Erste Group analysts upgraded Eli Lilly stock from Hold to Buy, citing a robust product demand and a promising pipeline of potential successes. The analysts highlighted the pharmaceutical company's ...
Jefferies analyst Akash Tewari maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on February 3 and set a price target of ...
Some you might hold only temporarily, while others you own for decades. David Jagielski (Eli Lilly): A forever stock you can ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback